Rectal cancer is a common type of colorectal cancer with high mortality and morbidity. The objective of this study was to identify gene signatures and uncover the potential mechanisms during rectal cancer samples. The gene expression profiles of GSE87211 data set were downloaded from GEO (Gene Expression Omnibus) database. The GSE87211 data set contained 2363 samples, including 203 rectal cancer samples and 160 matched mucosa control samples. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted, and protein–protein interaction network of differentially expressed genes (DEGs) was performed by Cytoscape. Then, Gene Expression Profiling Interactive Analysis (GEPIA) was applied to get the hub genes expression level and survival analysis between rectum adenocarcinoma (READ) tissues and normal tissues. In total, 846 DEGs were identified, including 402 upregulated genes and 444 downregulated genes. GO analysis showed that upregulated DEGs were enriched in inflammatory response, signal transduction, cell adhesion, immune response, and positive regulation of cell proliferation. KEGG pathway analysis showed that upregulated DEGs were enriched in cytokine–cytokine receptor interaction, Pi3K-Akt signaling pathway, and chemokine signaling pathway. The top 20 hub genes contained IL8, CXCR1, SSTR2, SST, CXCR2, GALR1, GAL, CXCL1, SSTR1, NPY1R, NPY, AGT, PPY, PPBP, CXCL2, CXCL6, CXCL11, CXCL3, GNG4, and GNGT1, and only four genes significantly increased expression levels with obvious changes of survival analysis in READ tissues based on GEPIA. Our study indicated that identified DEGs might promote our understanding of molecular mechanisms, which might be used as molecular targets or diagnostic biomarkers for the treatment of rectal cancer.
Get full access to this article
View all access options for this article.
References
1.
AranV., VictorinoA.P., ThulerL.C., and FerreiraC.G.2016. Colorectal cancer: Epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin. Colorectal Cancer, 15, 195–203.
2.
AshburnerM., BallC.A., BlakeJ.A., et al.2000. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25–29.
3.
BarrettT., WilhiteS.E., LedouxP., et al.2013. NCBI GEO: Archive for functional genomics data sets—Update. Nucleic Acids Res. 41, D991–D995.
4.
BondurantK.L., LundgreenA., HerrickJ.S., et al.2013. Interleukin genes and associations with colon and rectal cancer risk and overall survival. Int. J. Cancer, 132, 905–915.
5.
ChenW., ZhengR., BaadeP.D., et al.2016. Cancer statistics in China, 2015. CA Cancer J. Clin. 66, 115–132.
6.
ChiangJ.M., HsiehP.S., ChenJ.S., et al.2014. Rectal cancer level significantly affects rates and patterns of distant metastases among rectal cancer patients post curative-intent surgery without neoadjuvant therapy. World J. Surg. Oncol. 12, 197.
7.
DennisG.J., ShermanB.T., HosackD.A., et al.2003. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 4, 3.
8.
DingP., LiskaD., TangP., et al.2012. Pulmonary recurrence predominates after combined modality therapy for rectal cancer: An original retrospective study. Ann. Surg. 256, 111–116.
9.
DondooT.O., FukumoriT., DaizumotoK., et al.2017. Galectin-3 is implicated in tumor progression and resistance to anti-androgen drug through regulation of androgen receptor signaling in prostate cancer. Anticancer Res. 37, 125–134.
10.
DreyerS.B., PowellA.G., McSorleyS.T., et al.2017. The pretreatment systemic inflammatory response is an important determinant of poor pathologic response for patients undergoing neoadjuvant therapy for rectal cancer. Ann. Surg. Oncol. 24, 1295–1303.
11.
FazeliM.S., and KeramatiM.R.2015. Rectal cancer: A review. Med. J. Islam. Repub. Iran, 29, 171.
12.
FuW.N., ShangC., HuangD.F., et al.2006. Average-12.9 chromosome imbalances coupling with 15 differential expression genes possibly involved in the carcinogenesis, progression and metastasis of supraglottic laryngeal squamous cell cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 23, 7–11.
13.
GaoY.J., LiuL., LiS., et al.2018. Down-regulation of CXCL11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition. Onco Targets Ther. 11, 7333–7343.
14.
GasslerN., HerrI., KeithM., et al.2004. Wnt-signaling and apoptosis after neoadjuvant short-term radiotherapy for rectal cancer. Int. J. Oncol. 25, 1543–1549.
15.
GopalP., LuP., AyersG.D., et al.2014. Tumor deposits in rectal adenocarcinoma after neoadjuvant chemoradiation are associated with poor prognosis. Mod. Pathol. 27, 1281–1287.
16.
GraczA.D., WilliamsonI.A., RocheK.C., et al.2015. A high-throughput platform for stem cell niche co-cultures and downstream gene expression analysis. Nat. Cell. Biol. 17, 340–349.
17.
GuiS.L., TengL.C., WangS.Q., et al.2016. Overexpression of CXCL3 can enhance the oncogenic potential of prostate cancer. Int. Urol. Nephrol. 48, 701–709.
18.
GuoY., ZangY., LvL., et al.2017. IL8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NFkappaB pathway in prostate cancer. Mol. Med. Rep. 16, 9035–9042.
19.
HardawayA.L., HerroonM.K., RajagurubandaraE., et al.2015. Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer. Clin. Experi. Metastasis, 32, 353–368.
20.
HsuY.L., ChenY.J., ChangW.A., et al.2018. Interaction between tumor-associated dendritic cells and colon cancer cells contributes to tumor progression via CXCL1. Int. J. Mol. Sci. 19, E2427.
21.
HuL., WangH., ZhaoY., et al.2016. (125)I seeds radiation induces paraptosis-like cell death via PI3K/AKT signaling pathway in HCT116 cells. Biomed. Res. Int. 2016, 8145495.
22.
IkomaN., YouY.N., BednarskiB.K., et al.2017. Impact of recurrence and salvage surgery on survival after multidisciplinary treatment of rectal cancer. J. Clin. Oncol. 35, 2631–2638.
23.
JohnsonS.M., GulhatiP., RampyB.A., et al.2010. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J. Am. Coll. Surg. 210, 767–776, 776–778.
24.
KanehisaM., and GotoS.2000. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30.
25.
KimI., ChoiS., and KimS.2018. BRCA-Pathway: A structural integration and visualization system of TCGA breast cancer data on KEGG pathways. BMC Bioinformatics, 19, 42.
26.
KollmarO., JunkerB., RupertusK., et al.2007. Studies on MIP-2 and CXCR2 expression in a mouse model of extrahepatic colorectal metastasis. Eur. J. Surg. Oncol. 33, 803–811.
27.
KralJ., KorenkovaV., NovosadovaV., et al.2018. Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer. Carcinogenesis, 39, 1359–1367.
28.
LandiS., MorenoV., Gioia-PatricolaL., et al.2003. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 63, 3560–3566.
29.
LiJ., ChenC., BiX., et al.2017. DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer. Gene, 630, 1–7.
30.
LiuY., ChewM.H., ThamC.K., et al.2016. Methylation of serum SST gene is an independent prognostic marker in colorectal cancer. Am. J. Cancer Res. 6, 2098–2108.
31.
MaJ.C., SunX.W., SuH., et al.2017. Fibroblast-derived CXCL12/SDF-1alpha promotes CXCL6 secretion and co-operatively enhances metastatic potential through the PI3K/Akt/mTOR pathway in colon cancer. World J. Gastroenterol. 23, 5167–5178.
32.
ManfrediS., BouvierA.M., LepageC., et al.2006. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br. J. Surg. 93, 1115–1122.
33.
MitryE., GuiuB., CosconeaS., et al.2010. Epidemiology, management and prognosis of colorectal cancer with lung metastases: A 30-year population-based study. Gut, 59, 1383–1388.
34.
ModaraiS.R., OpdenakerL.M., ViswanathanV., et al.2016. Somatostatin signaling via SSTR1 contributes to the quiescence of colon cancer stem cells. BMC Cancer, 16, 941.
35.
MokhlesS., MacbethF., FarewellV., et al.2016. Meta-analysis of colorectal cancer follow-up after potentially curative resection. Br. J. Surg. 103, 1259–1268.
36.
MullerH., SchmidtD., DreherF., et al.2011. Gene ontology analysis of the centrosome proteomes of Drosophila and human. Commun. Integr. Biol. 4, 308–311.
37.
OgataH., GotoS., SatoK., et al.1999. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 27, 29–34.
38.
OkadaH., MizunoM., IkedaN., et al.1996. Epithelial cell proliferation during colonic chemical carcinogenesis in the rat. J. Gastroenterol. Hepatol. 11, 686–691.
39.
PalJ., PatilV., MondalB., et al.2016. Epigenetically silenced GNG4 inhibits SDF1alpha/CXCR4 signaling in mesenchymal glioblastoma. Genes Cancer, 7, 136–147.
40.
PerezR., WuN., KlipfelA.A., et al.2003. A better cell cycle target for gene therapy of colorectal cancer: cyclin G. J. Gastrointest. Surg. 7, 884–889.
41.
RobinsonJ.R., NewcombP.A., HardikarS., et al.2017. Stage IV colorectal cancer primary site and patterns of distant metastasis. Cancer Epidemiol. 48, 92–95.
42.
RoxburghC.S., SalmondJ.M., HorganP.G., et al.2009. The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers. J. Gastrointest. Surg. 13, 2011–2018.
43.
SakaiE., FukuyoM., OhataK., et al.2016. Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway. Int. J. Cancer, 138, 1634–1644.
44.
SeeA.L., ChongP.K., LuS.Y., et al.2014. CXCL3 is a potential target for breast cancer metastasis. Curr. Cancer Drug Targets, 14, 294–309.
45.
ShannonP., MarkielA., OzierO., et al.2003. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504.
46.
SharafeldinN., SlatteryM.L., LiuQ., et al.2017. Multiple gene-environment interactions on the angiogenesis gene-pathway impact rectal cancer risk and survival. Int. J. Environ. Res. Public Health. 14, E1146.
47.
SiegelR.L., MillerK.D., and JemalA.2018. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7–30.
48.
SlatteryM.L., LundgreenA., KadlubarS.A., et al.2013. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol. Carcinog. 52, 155–166.
49.
SzklarczykD., GableA.L., LyonD., et al.2018. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607–D613.
50.
TakeiY., KadomatsuK., MatsuoS., et al.2001. Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res. 61, 8486–8491.
51.
TanabeK.K., EllisL.M., and SayaH.1993. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet. 341, 725–726.
52.
TangZ., LiC., KangB., et al.2017. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98–W102.
53.
TianH., HuangP., ZhaoZ., et al.2014. HIF-1alpha plays a role in the chemotactic migration of hepatocarcinoma cells through the modulation of CXCL6 expression. Cell. Physiol. Biochem. 34, 1536–1546.
54.
TsunodaT., NakamuraT., IshimotoK., et al.2001. Upregulated expression of angiogenesis genes and down regulation of cell cycle genes in human colorectal cancer tissue determined by cDNA macroarray. Anticancer Res. 21, 137–143.
55.
UliviP., MercataliL., CasoniG.L., et al.2013. Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One, 8, e57401.
56.
WangH., WangL., ZhangH., et al.2013. (1)H NMR-based metabolic profiling of human rectal cancer tissue. Mol. Cancer, 12, 121.
57.
WangL., ZhangC., XuJ., et al.2016. CXCL1 gene silencing inhibits HGC803 cell migration and invasion and acts as an independent prognostic factor for poor survival in gastric cancer. Mol. Med. Rep. 14, 4673–4679.
58.
WangZ., WangZ., LiG., et al.2017. CXCL1 from tumor-associated lymphatic endothelial cells drives gastric cancer cell into lymphatic system via activating integrin beta1/FAK/AKT signaling. Cancer Lett. 385, 28–38.
59.
WatanabeK., SaitoN., SugitoM., et al.2011. Predictive factors for pulmonary metastases after curative resection of rectal cancer without preoperative chemoradiotherapy. Dis. Colon Rectum, 54, 989–998.
60.
WongB.Y., LauB.H., YamasakiT., et al.1993. Inhibition of dexamethasone-induced cytochrome P450-mediated mutagenicity and metabolism of aflatoxin B1 by Chinese medicinal herbs. Eur. J. Cancer Prev. 2, 351–356.
61.
XinH., CaoY., ShaoM.L., et al.2018. Chemokine CXCL3 mediates prostate cancer cells proliferation, migration and gene expression changes in an autocrine/paracrine fashion. Int. Urol. Nephrol. 50, 861–868.
62.
XiongD., PanJ., ZhangQ., et al.2017. Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents. Oncotarget, 8, 18885–18900.
63.
XueM.Q., LiuJ., SangJ.F., et al.2017. Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer. Oncotarget, 8, 48930–48937.
64.
ZengY.J., LaiW., WuH., et al.2016. Neuroendocrine-like cells-derived CXCL10 and CXCL11 induce the infiltration of tumor-associated macrophage leading to the poor prognosis of colorectal cancer. Oncotarget, 7, 27394–27407.
65.
ZhangL., ZhangL., LiH., et al.2016. CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation. Sci. Rep. 6, 27426.
66.
ZhiqinW., PalaniappanS., and RajaA.R.2014. Inflammatory bowel disease-related colorectal cancer in the Asia-Pacific region: Past, present, and future. Intestinal Res. 12, 194–204.
67.
ZouY., XiaoX., LiY., et al.2009. Somatostatin analogues inhibit cancer cell proliferation in an SSTR2-dependent manner via both cytostatic and cytotoxic pathways. Oncol. Rep. 21, 379–386.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
